alanine
Phase 1Small molecule
alanine is one of 35 small molecule programs targeting Polyp. It is currently in Phase 1.
2
Indications
3
Total Trials
2
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
77 competitors in Type 1 Diabetes
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Invokana
WWim Janssens
Approved
Ozempic
Novo NordiskPhase 3
Singulair
OOrganon and Co
Approved
Stelara
Johnson & JohnsonPhase 3
Inpefa
LLexicon Pharmaceuticals
Phase 3
Tricor
JJagotec
Phase 3
Atorvastatin Calcium
Merck & Co.Phase 3
Diamox
TevaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Low Birth Weight1 trial
Polyp1 trial
Type 1 Diabetes1 trial
The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 Diabetes
Active, not recruiting·—·N/A·NCT06881472·10 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for alanine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details